Deucrictibant Phase 3 Data Shows Rapid, Sustained Efficacy for Angioedema, Meeting All Endpoints
PHVS has more than doubled off its 52-week low of $11.51.
Summary
Pharvaris presented strong final Phase 3 RAPIDe-3 data for its lead candidate, deucrictibant, in hereditary angioedema (HAE) at AAAAI 2026. The oral immediate-release capsule met its primary endpoint, demonstrating a median time to onset of symptom relief of 1.28 hours versus over 12 hours for placebo, and achieved all 11 secondary efficacy endpoints. Additionally, final results from the Phase 2 CHAPTER-1 open-label extension study showed long-term safety and a significant reduction in HAE attack rates, from 2.18 attacks/month to 0.12 attacks/month, with approximately half of participants becoming attack-free. This highly positive data significantly de-risks deucrictibant, positioning it as a potentially differentiated and standard-of-care treatment for both on-demand and prophylactic use in HAE. This news is a major catalyst for the company, validating its clinical development strategy. Traders will be watching for upcoming regulatory submissions and further commercialization updates.
At the time of this announcement, PHVS was trading at $28.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $11.51 to $29.80. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.